Gruss & Co’s Moderna MRNA Stock Holding History

Gruss & Co’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-5,000	Closed	-$898K	–	27
2022 Q4	$898K	Buy	+5,000	New	+$818K	5.55%	7

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Gruss & Co's MRNA Position: Q1 2023 in Review

Gruss & Co sold out of Moderna (MRNA) in Q1 2023, closing a stake of 5,000 shares — an estimated $898K sold.

Gruss & Co first reported a position in MRNA in Q4 2022 and held it in 1 quarter. The position peaked at $898K in Q4 2022. 1,016 funds tracked by Wall St. Rank hold MRNA as of Q1 2023.

Gruss & Co reported no remaining Moderna position as of Q1 2023 after selling out during the quarter.
Gruss & Co sold 5,000 Moderna shares in Q1 2023, an estimated $898K.
Gruss & Co first reported a position in Moderna in Q4 2022 and held it in 1 quarter.
Gruss & Co's Moderna position peaked at $898K in Q4 2022.
1,016 funds tracked by Wall St. Rank held Moderna as of Q1 2023.

Based on Gruss & Co's 13F filing for Q1 2023, filed 12 May 2023.